Anti-tumour necrosis factor-alpha agent therapy, compared with conventional therapy, reduces the relapse of uveitis in patients with behcet's disease: A systematic review of controlled trials.

ABSTRACT: Purpose: Anti-tumour necrosis factor-alpha (TNF-α) agents are often used for Behçet's disease (BD) in clinical practice, but they have not been validated by a high level of evidence. We systematically reviewed published controlled trials to investigate the efficacy and safety of anti-TNF-α therapy and summarize the efficacy of anti-TNF-α therapy relative to the available therapeutic options. Methods: A systematic database search was conducted (PubMed, Embase and Cochrane) using specific search terms. All controlled studies of anti-TNF-α treatment of BD patients prior to December 2021 were included. Single-arm studies were excluded. The decision of whether to incorporate data into the meta-analysis or summarize the data by qualitative synthesis was based on the results of the

SUBMITTER: Zhou X 

PROVIDER: S-EPMC9438790 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature